Dexcom stock surged Thursday after the Food and Drug Administration cleared its newest diabetes device for an extended 15-day ...

DexCom stock was on the rise Thursday after the maker of medical technology said it had received clearance from the U.S. Food ...

The longer wear time should improve Dexcom’s margins and help it compete with Abbott, RBC Capital Markets analyst Shagun ...

CGM approved by FDA for adults with diabetes; U.S. launch set for late 2025 with extended wear and advanced tracking features ...

The US Food and Drug Administration has cleared the latest version to last 5 days longer than previously for adult users.

The Food and Drug Administration has cleared diabetes-management firm DexCom's new continuous glucose monitoring (CGM) system ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...

Dexcom (Nadsaq:DXCM) announced today that the FDA cleared its G7 15-day continuous glucose monitoring (CGM) system.

DexCom DXCM underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing ...

The San Diego-based medical device company stated that the Dexcom G7 15 Day has an overall Mean Absolute Relative Difference (MARD) of 8.0%, showcasing its precision in glucose level readings. The ...

Mizuho analyst Anthony Petrone initiated coverage of DexCom (DXCM) with an Outperform rating and $85 price target The firm cites its positive ...